ReShape Lifesciences Inc. reported Impairment of long-lived assets for the third quarter ended September 30, 2023. For the quarter, the company reported Impairment of long-lived assets of $777,000 against $7,429,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.168 USD | +0.18% | -0.77% | -32.72% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
04-01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.72% | 3.94M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023